Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000759789 | SCV000889358 | uncertain significance | not provided | 2022-12-05 | criteria provided, single submitter | clinical testing | The HBB c.-10A>G variant has not been reported in the published literature. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity. Based on the available information, we are unable to determine the clinical significance of this variant. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001175410 | SCV001338949 | uncertain significance | not specified | 2020-03-31 | criteria provided, single submitter | clinical testing | Variant summary: HBB c.-10A>G is located in the untranslated mRNA region upstream of the initiation codon. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 2e-05 in 251052 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.-10A>G in individuals affected with Beta Thalassemia and no experimental evidence demonstrating its impact on protein function have been reported. One ClinVar submitter (evaluation after 2014) cites the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Natera, |
RCV001825504 | SCV002091627 | uncertain significance | beta Thalassemia | 2020-05-18 | no assertion criteria provided | clinical testing |